Novel cyclic N-hydroxamic acid inhibitors of TNF- synthesis and MMP-13

Author：

ISSN： 1354-3776

Source： Expert Opinion on Therapeutic Patents, Vol.10, Iss.12, 2000-12, pp. : 1951-1956

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Novel N-hydroxamic acid hydrazide inhibitors of TNF- synthesis

Expert Opinion on Therapeutic Patents, Vol. 10, Iss. 10, 2000-10 ,pp. : 1617-1621

Informa Healthcare

Access to resources Recommend Favorite

N-hydroxamic inhibitors of CD23

Expert Opinion on Therapeutic Patents, Vol. 12, Iss. 1, 2002-01 ,pp. : 135-137

Informa Healthcare

Access to resources Recommend Favorite

Arylsulphonamide hydroxamic acids as potent inhibitors of MMP-13

Expert Opinion on Therapeutic Patents, Vol. 9, Iss. 9, 1999-09 ,pp. : 1303-1307

Informa Healthcare

Access to resources Recommend Favorite

Design, Synthesis, and Biological Evaluation of Vanillin Hydroxamic Acid Derivatives as Novel Peptide Deformylase Inhibitors

Current Computer - Aided Drug Design, Vol. 14, Iss. 1, 2018-03 ,pp. : 95-101

Bentham Science Publishers

Access to resources Recommend Favorite

Cyclic sulphone MMP inhibitors

Expert Opinion on Therapeutic Patents, Vol. 10, Iss. 12, 2000-12 ,pp. : 1947-1950

Informa Healthcare

Access to resources Recommend Favorite